Deregulated expression of the polycomb-group protein SUZ12 target genes characterizes mantle cell lymphoma.

Polycomb proteins are known to be of great importance in human cancer pathogenesis. SUZ12 is a component of the Polycomb PRC2 complex that, along with EZH2, is involved in embryonic stem cell differentiation. EZH2 plays an essential role in many cancer types, but an equivalent involvement of SUZ12 has not been as thoroughly demonstrated. Here we show that SUZ12 is anomalously expressed in human primary tumors, especially in mantle cell lymphoma (MCL), pulmonary carcinomas and melanoma, and is associated with gene locus amplification in some cases. Using MCL as a model, functional and genomic studies demonstrate that SUZ12 loss compromises cell viability, increases apoptosis, and targets genes involved in central oncogenic pathways associated with MCL pathogenesis. Our results support the hypothesis that the abnormal expression of SUZ12 accounts for some of the unexplained features of MCL, such as abnormal DNA repair and increased resistance to apoptosis.

[1]  W. Alexander,et al.  Novel zinc finger gene implicated as myc collaborator by retrovirally accelerated lymphomagenesis in Eμ-myc transgenic mice , 1991, Cell.

[2]  Anton Berns,et al.  Identification of cooperating oncogenes in Eμ-myc transgenic mice by provirus tagging , 1991, Cell.

[3]  J.M. Adams,et al.  Cyclin D1 transgene impedes lymphocyte maturation and collaborates in lymphomagenesis with the myc gene. , 1994, The EMBO journal.

[4]  M. James,et al.  Molecular characterization of 11q deletions points to a pathogenic role of the ATM gene in mantle cell lymphoma. , 1999, Blood.

[5]  R. Kingston,et al.  Stabilization of Chromatin Structure by PRC1, a Polycomb Complex , 1999, Cell.

[6]  F. Bosch,et al.  Translocation (11;14)(q13;q32) and preferential involvement of chromosomes 1, 2, 9, 13, and 17 in mantle cell lymphoma. , 1999, Cancer genetics and cytogenetics.

[7]  E. Campo,et al.  BMI-1 gene amplification and overexpression in hematological malignancies occur mainly in mantle cell lymphomas. , 2001, Cancer research.

[8]  O. Kallioniemi,et al.  Tissue microarray technology for high-throughput molecular profiling of cancer. , 2001, Human molecular genetics.

[9]  L. Medeiros,et al.  Cytogenetic findings in mantle cell lymphoma cases with a high level of peripheral blood involvement have a distinct pattern of abnormalities. , 2001, American journal of clinical pathology.

[10]  M. Lohuizen,et al.  The bmi-1 oncoprotein is differentially expressed in non-small cell lung cancer and correlates with INK4A-ARF locus expression , 2001, British Journal of Cancer.

[11]  C. Meijer,et al.  Coexpression of BMI-1 and EZH2 polycomb-group proteins is associated with cycling cells and degree of malignancy in B-cell non-Hodgkin lymphoma. , 2001, Blood.

[12]  J. Sklar,et al.  Frequent fusion of the JAZF1 and JJAZ1 genes in endometrial stromal tumors , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[13]  V. Pirrotta,et al.  Drosophila Enhancer of Zeste/ESC Complexes Have a Histone H3 Methyltransferase Activity that Marks Chromosomal Polycomb Sites , 2002, Cell.

[14]  David Baltimore,et al.  Germline Transmission and Tissue-Specific Expression of Transgenes Delivered by Lentiviral Vectors , 2002, Science.

[15]  Brigitte Wild,et al.  Histone Methyltransferase Activity of a Drosophila Polycomb Group Repressor Complex , 2002, Cell.

[16]  D. Reinberg,et al.  Histone methyltransferase activity associated with a human multiprotein complex containing the Enhancer of Zeste protein. , 2002, Genes & development.

[17]  R. Lothe,et al.  Genome profiles of familial/bilateral and sporadic testicular germ cell tumors , 2002, Genes, chromosomes & cancer.

[18]  S. Dhanasekaran,et al.  The polycomb group protein EZH2 is involved in progression of prostate cancer , 2002, Nature.

[19]  J. Shah,et al.  Amplification of the 3q26.3 locus is associated with progression to invasive cancer and is a negative prognostic factor in head and neck squamous cell carcinomas. , 2002, The American journal of pathology.

[20]  Hengbin Wang,et al.  Role of Histone H3 Lysine 27 Methylation in Polycomb-Group Silencing , 2002, Science.

[21]  M. Daly,et al.  PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes , 2003, Nature Genetics.

[22]  Debashis Ghosh,et al.  EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[23]  P. Farnham,et al.  Identification of the polycomb group protein SU(Z)12 as a potential molecular target for human cancer therapy. , 2003, Molecular cancer therapeutics.

[24]  L. Staudt,et al.  The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. , 2003, Cancer cell.

[25]  Kristian Helin,et al.  EZH2 is downstream of the pRB‐E2F pathway, essential for proliferation and amplified in cancer , 2003, The EMBO journal.

[26]  Nerea Martínez,et al.  The molecular signature of mantle cell lymphoma reveals multiple signals favoring cell survival. , 2003, Cancer research.

[27]  D. Reinberg,et al.  Silencing of human polycomb target genes is associated with methylation of histone H3 Lys 27. , 2004, Genes & development.

[28]  G. Lyons,et al.  The Polycomb Ezh2 methyltransferase regulates muscle gene expression and skeletal muscle differentiation. , 2004, Genes & development.

[29]  C. Meijer,et al.  Site-specific expression of polycomb-group genes encoding the HPC-HPH/PRC1 complex in clinically defined primary nodal and cutaneous large B-cell lymphomas. , 2004, The American journal of pathology.

[30]  N. Carter,et al.  Array Comparative Genomic Hybridization Analysis of Colorectal Cancer Cell Lines and Primary Carcinomas , 2004, Cancer Research.

[31]  J. Cigudosa,et al.  Phenotypic characterization of BRCA1 and BRCA2 tumors based in a tissue microarray study with 37 immunohistochemical markers , 2005, Breast Cancer Research and Treatment.

[32]  Yi Zhang,et al.  SUZ12 is required for both the histone methyltransferase activity and the silencing function of the EED-EZH2 complex. , 2004, Molecular cell.

[33]  C. Meijer,et al.  Unique polycomb gene expression pattern in Hodgkin's lymphoma and Hodgkin's lymphoma-derived cell lines. , 2004, The American journal of pathology.

[34]  Juan F. García,et al.  Abnormal PcG protein expression in Hodgkin's lymphoma. Relation with E2F6 and NFκB transcription factors , 2004, The Journal of pathology.

[35]  Kristian Helin,et al.  Suz12 is essential for mouse development and for EZH2 histone methyltransferase activity , 2004, The EMBO journal.

[36]  Stephen A Boorjian,et al.  Increased Expression of the Polycomb Group Gene, EZH2, in Transitional Cell Carcinoma of the Bladder , 2005, Clinical Cancer Research.

[37]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[38]  Anke Sparmann,et al.  Polycomb silencers control cell fate, development and cancer , 2006, Nature Reviews Cancer.

[39]  Henriette O'Geen,et al.  Suz12 binds to silenced regions of the genome in a cell-type-specific manner. , 2006, Genome research.

[40]  A. Chinnaiyan,et al.  Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells , 2006, Molecular Cancer Therapeutics.

[41]  Radu Dobrin,et al.  Dissecting self-renewal in stem cells with RNA interference , 2006, Nature.

[42]  Megan F. Cole,et al.  Control of Developmental Regulators by Polycomb in Human Embryonic Stem Cells , 2006, Cell.

[43]  Kristian Helin,et al.  Genome-wide mapping of Polycomb target genes unravels their roles in cell fate transitions. , 2006, Genes & development.

[44]  Joaquín Dopazo,et al.  Next station in microarray data analysis: GEPAS , 2006, Nucleic Acids Res..

[45]  Juan F. García,et al.  Interphase fluorescence in situ hybridization assay for the detection of rearrangements of the EVI-1 locus in chromosome band 3q26 in myeloid malignancies. , 2003, Haematologica.

[46]  J. Cigudosa,et al.  Variability in the expression of polycomb proteins in different normal and tumoral tissues. A pilot study using tissue microarrays , 2006, Modern Pathology.

[47]  E. Oliva,et al.  High Frequency of JAZF1-JJAZ1 Gene Fusion in Endometrial Stromal Tumors With Smooth Muscle Differentiation by Interphase FISH Detection , 2007, The American journal of surgical pathology.

[48]  A. Iafrate,et al.  Validation of chromogenic in situ hybridization for detection of EGFR copy number amplification in nonsmall cell lung carcinoma , 2007, Modern Pathology.

[49]  Y. Kotake,et al.  pRB family proteins are required for H3K27 trimethylation and Polycomb repression complexes binding to and silencing p16INK4alpha tumor suppressor gene. , 2007, Genes & development.

[50]  E. Campo,et al.  Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics , 2007, Nature Reviews Cancer.

[51]  Qiang Yu,et al.  Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. , 2007, Genes & development.

[52]  Megan F. Cole,et al.  Connecting microRNA Genes to the Core Transcriptional Regulatory Circuitry of Embryonic Stem Cells , 2008, Cell.

[53]  S. Ropero,et al.  A microRNA DNA methylation signature for human cancer metastasis , 2008, Proceedings of the National Academy of Sciences.

[54]  W. Chan,et al.  Gcet1 (centerin), a highly restricted marker for a subset of germinal center-derived lymphomas. , 2008, Blood.

[55]  Nerea Martínez,et al.  Somatic hypermutation signature in B-cell low-grade lymphomas , 2008, Haematologica.

[56]  M. Piris,et al.  Lentiviral (HIV)-based RNA interference screen in human B-cell receptor regulatory networks reveals MCL1-induced oncogenic pathways. , 2008, Blood.

[57]  A. Telenius,et al.  High-resolution whole genome tiling path array CGH analysis of CD34+ cells from patients with low-risk myelodysplastic syndromes reveals cryptic copy number alterations and predicts overall and leukemia-free survival. , 2008, Blood.

[58]  Benjamin Haibe-Kains,et al.  microRNA-29c and microRNA-223 down-regulation has in vivo significance in chronic lymphocytic leukemia and improves disease risk stratification. , 2009, Blood.